Special Issue "Treatment of Affective Disorders: Adverse Effects, Drug Interactions and Tolerability"
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 9876
Interests: treatment of depression, bipolar disorder, and anxiety disorders; coexistence of pain and psychiatric disorders; drug treatment of refractory disorders; drug interactions and side effects; neuropsychiatry
Effective treatment of affective disorders may be challenging. Up to 40% of depressive patients may not achieve satisfactory response to first-line treatment, and in a one-third of them, drug resistance persists after a number of pharmacological interventions, constituting a serious therapeutic issue. The problem of suboptimal and unsatisfactory treatment outcomes becomes even more complex in bipolar disorder due to the higher incidence of drug resistance and the occurrence of mixed episodes. Therefore, treatment frequently requires the use of a combination of drugs belonging to different medication classes. Simultaneous use of two or more drugs poses the risk of interactions. This results in drug toxicity effects, multiplication of adverse effects, decreased tolerability and, importantly, significant risk of non-compliance, treatment discontinuation or lack of functional remission. Another issue is the high comorbidity of somatic diseases and affective disorders, often resulting in the accumulation of side effects and interactions between psychotropics and non-psychiatric drugs. Thus, contraindications resulting from general medical state should also be taken into account. In this Special Issue, our aim will be to focus on those challenging aspects of the treatment of affective disorders—adverse effects, drug interactions, and tolerability.
Dr. Marcin Siwek
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- major depression
- bipolar disorder
- mood stabilizers